Centogene (CNTGF) 6-K 16 Dec 20 2020 Q3 CENTOGENE Reports Third-Quarter 2020 Financial Results and Increases Full Year Guidance Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Sep. 30, 2020
Document and Entity Information
Entity Registrant Name	Centogene N.V.
Entity Central Index Key	0001757097
Document Type	6-K
Document Period End Date	Sep. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	Q3

Unaudited interim condensed con

Unaudited interim condensed consolidated statements of comprehensive loss - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Unaudited interim condensed consolidated statements of comprehensive loss
Revenue	€ 36,305	€ 11,638	€ 58,129	€ 33,559
Cost of sales	26,059	6,641	39,892	19,499
Gross profit	10,246	4,997	18,237	14,060
Research and development expenses	4,796	2,011	10,606	6,119
General administrative expenses	8,373	4,884	24,038	16,487
Selling expenses	1,300	1,788	6,012	6,144
Impairment of financial assets	1,147	92	2,821	554
Other operating income	679	935	2,425	2,623
Other operating expenses	53		191	2
Real estate transfer tax expenses		1,200		1,200
Operating loss	(4,744)	(2,843)	(23,006)	(13,823)
Interest and similar income			6	12
Interest and similar expense	793	1,433	1,504	1,865
Financial costs, net	(793)	(1,433)	(1,498)	(1,853)
Loss before taxes	(5,537)	(4,276)	(24,504)	(15,676)
Income tax expenses	103		232	163
Loss for the period	(5,640)	(4,276)	(24,736)	(15,839)
Other comprehensive income/(loss), all attributable to equity holders of the parent	(66)	(1)	4	9
Total comprehensive loss	(5,706)	(4,277)	(24,732)	(15,830)
Attributable to:
Equity holders of the parent	(5,708)	(4,247)	(24,671)	(15,674)
Noncontrolling interests	2	(30)	(61)	(156)
Total comprehensive loss	€ (5,706)	€ (4,277)	€ (24,732)	€ (15,830)
Loss per share - Basic and diluted	€ (0.27)	€ (0.27)	€ (1.20)	€ (0.99)

Unaudited interim condensed c_2

Unaudited interim condensed consolidated statements of financial position - EUR (€) € in Thousands	Sep. 30, 2020	Dec. 31, 2019
Noncurrent assets
Intangible assets	€ 16,405	€ 14,145
Property, plant and equipment	13,585	8,376
Right-of-use assets	23,915	24,932
Other assets	1,953	1,948
Non-current assets	55,858	49,401
Current assets
Inventories	7,291	1,809
Trade receivables and contract assets	25,787	16,593
Other assets	4,055	8,612
Cash and cash equivalents	28,748	41,095
Current assets	65,881	68,109
Total assets	121,739	117,510
Equity
Issued capital	2,653	2,383
Capital reserve	122,801	98,099
Retained earnings and other reserves	(66,073)	(40,622)
Noncontrolling interests	(26)	(938)
Equity	59,355	58,922
Noncurrent liabilities
Noncurrent loans	501	1,578
Lease liabilities	18,052	18,069
Deferred tax liabilities	219
Government grants	9,296	9,941
Non-current liabilities	28,068	29,588
Current liabilities
Government grants	1,350	1,348
Current loans	4,619	3,688
Lease liabilities	3,295	3,635
Trade payables	12,052	8,554
Other liabilities	13,000	11,775
Current liabilities	34,316	29,000
Equity and liabilities	€ 121,739	€ 117,510

Unaudited interim condensed c_3

Unaudited interim condensed consolidated statements of cash flows - EUR (€) € in Thousands	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019
Operating activities
Loss before taxes	€ (24,504)	€ (15,676)
Adjustments to reconcile loss to cash flow from operating activities
Amortization and depreciation	6,943	4,461
Interest income	(6)	(12)
Interest expense	1,504	1,865
Gain on the disposal of property, plant and equipment		(532)
Expected credit loss allowances on trade receivables and contract assets	2,821	554
Sharebased payment expenses	2,542	5,299
Real Estate transfer tax expenses		1,200
Other noncash items	(1,800)	(26)
Changes in operating assets and liabilities
Inventories	(5,482)	(240)
Trade receivables and contract assets	(12,015)	(3,336)
Other assets	5,605	(739)
Trade payables	3,498	3,280
Other liabilities	1,225	448
Cash flow used in operating activities	(19,669)	(3,454)
Investing activities
Cash paid for investments in intangible assets	(4,781)	(5,366)
Cash paid for investments in property, plant and equipment	(6,641)	(1,266)
Grants received for investment in property, plant and equipment	390	341
Cash received from the disposals of property, plant and equipment		19,800
Interest received	6	12
Cash flow used in investing activities	(11,026)	13,521
Financing activities
Cash received from issuance of shares	22,430
Cash paid for acquisition of non-wholly owned subsidiary	(75)
Cash received from loans	1,114	1,545
Cash repayments of loans	(1,260)	(11,871)
Cash received from finance leases		470
Cash repayments of lease liabilities	(2,833)	(1,507)
Interest paid	(1,028)	(1,865)
Cash flow used in financing activities	18,348	(13,228)
Changes in cash and cash equivalents	(12,347)	(3,161)
Cash and cash equivalents at the beginning of the period	41,095	9,222
Cash and cash equivalents at the end of the period	€ 28,748	€ 6,061

Unaudited interim condensed c_4

Unaudited interim condensed consolidated statements of changes in equity - EUR (€) € in Thousands	Total	Issued capital	Capital reserve	Currency translation reserve	Retained earnings	Non-controlling interests	Total
Balance at beginning of the period at Dec. 31, 2018	€ 27,281	€ 1,903	€ 45,342	€ (16)	€ (19,948)	€ (757)	€ 26,524
Loss for the period	(15,683)				(15,683)	(156)	(15,839)
Other comprehensive loss	9			9			9
Total comprehensive loss	(15,674)			9	(15,683)	(156)	(15,830)
Share-based payments	494		494				494
Balance at end of the period at Sep. 30, 2019	12,101	1,903	45,836	(7)	(35,631)	(913)	11,188
Balance at beginning of the period at Dec. 31, 2019	59,860	2,383	98,099		(40,622)	(938)	58,922
Loss for the period	(24,675)				(24,675)	(61)	(24,736)
Other comprehensive loss	4			4			4
Total comprehensive loss	(24,671)	0	0	4	(24,675)	(61)	(24,732)
Share-based payments	2,542		2,542				2,542
Issuance of shares	23,209	240	22,969				23,209
Exercise of options		30	(30)
Transaction costs	(779)		(779)				(779)
Disposal of non-wholly owned subsidiary						268	268
Acquisition of non-wholly owned subsidiary	(780)				(780)	705	(75)
Balance at end of the period at Sep. 30, 2020	€ 59,381	€ 2,623	€ 122,831	€ 4	€ (66,077)	€ (26)	€ 59,355

General company information

General company information	9 Months Ended
	Sep. 30, 2020
General company information
General company information	1 General company information Centogene N.V. (“the Company”) and its subsidiaries (“the Group”) focus on rare diseases and seek to transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The mission of the Company is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our knowledge of the global rare disease market, including epidemiological and clinical data and innovative biomarkers. On November 7, 2019, the Company completed an initial public offering (“IPO”) and has since been listed on Nasdaq Global Market under stock code “CNTG”. We have historically conducted our business through Centogene AG (which is now known as Centogene GmbH), and therefore our historical financial statements present the results of operations and financial condition of Centogene AG and its controlled subsidiaries. In connection with our initial public offering, Centogene N.V. became the holding company of Centogene AG on November 12, 2019, and the historical consolidated financial statements of Centogene AG became the historical consolidated financial statements of Centogene N.V. Centogene N.V. is a public company with limited liability incorporated in the Netherlands, with registered office located at Am Strande 7 in 18055 Rostock, Germany and Dutch trade register number 72822872. On March 5, 2020, the Company resolved that Centogene AG shall be converted into a German limited liability company and renamed Centogene GmbH. Such conversion became effective upon the registration in the German commercial register on June 29, 2020. Unless otherwise stated, “Centogene GmbH” also refers to the historical operations of Centogene AG throughout the notes. In July 2020, the Company completed a follow-on public offering of 3,500,000 common shares of the Company (the “July 2020 Offering”), consisting of 2,000,000 common shares offered by the Company and 1,500,000 common shares offered by selling shareholders at a price to the public of USD 14.00 per common share (i.e. EUR 12.71 per share). Aggregate offering proceeds, net of underwriting discounts, commissions and transaction costs, were EUR 22 million to the Company.

Basis of preparation

Basis of preparation	9 Months Ended
	Sep. 30, 2020
Basis of preparation
Basis of preparation	2 Basis of preparation The interim condensed consolidated financial statements for the three and nine months ended September 30, 2019 and 2020 have been prepared in accordance with IAS 34 Interim Financial Reporting. The interim condensed consolidated financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual consolidated financial statements as of December 31, 2018 and 2019 and for the three years ended December 31, 2019. Unless otherwise specified, "the Company" refers to Centogene N.V. and Centogene GmbH throughout the remainder of these notes, while "the Group" refers to Centogene N.V., Centogene GmbH and its subsidiaries. The accounting policies adopted in the preparation of the interim condensed consolidated financial statements are consistent with those followed in the preparation of the Group’s annual consolidated financial statements for the year ended December 31, 2019, except for the adoption of new standards effective as of January 1, 2020 (see note 2.2). The Group has not early adopted any standard, interpretation or amendment that has been issued but is not yet effective. Several other amendments and interpretations apply for the first time in 2020, but do not have an impact on the interim condensed consolidated financial statements of the Group. These interim condensed consolidated financial statements are presented in euro, which is the Group's functional currency. Unless otherwise specified, all financial information presented in euro is rounded to the nearest thousand (EUR k) in line with customary commercial practice. 2.1 COVID-19 reporting Due to the growth and significance of the COVID-19 business in relation to the total activities of the Group, the COVID-19 testing business is managed and reported as a separate segment beginning in the third quarter of 2020. In the second quarter 2020 report, furnished to the SEC on Form 6-K on September 23, 2020, the financial impact of the COVID-19 business has been reported as a part of our Diagnostics segment, whereas it has been separated from the Diagnostics segment and included in the year-to-date COVID-19 financials in this report. In the third quarter of 2020, the Company entered into a collaboration agreement with Dr. Bauer Laboratoriums GmbH, Rostock (hereafter ‘Bauer GmbH’). Bauer GmbH supports Centogene in certain areas of its COVID-19 testing business by providing the medical laboratory services to facilitate Centogene to perform its COVID-19 testing business activities. Bauer GmbH is wholly owned by a long-time employee of Centogene, who from a medical perspective and by observing the Medical Association's professional code of conduct continues to operate as an independent medical physician. As per the criteria in IFRS 10, Centogene assessed the control it has over Bauer GmbH and concluded to consolidate the activities of Bauer GmbH in the Group from the third quarter of 2020. Centogene does not own any shares in Bauer GmbH. However, based on the analysis of all facts and circumstances surrounding the close collaboration with Bauer GmbH and the employment relationship with the sole shareholder of Bauer GmbH, this shareholder is considered as a de facto agent. Centogene meets the criteria of the control model under IFRS 10 as it has exposure to variable returns and the ability to use power to affect returns. Bauer GmbH has a share in the net result of the respective COVID-19 testing business which has been accounted for under non-controlling interest. 2.2 The following amendments and interpretations apply for the first time in 2020 and had no impact on the unaudited interim condensed consolidated financial statements of the Group: · Amendments to IAS 1 and IAS 8: Definition of Material · Amendments to IFRS 3: Definition of a Business · Amendments to IFRS 7, IFRS 9 and IAS 39: Interest Rate Benchmark Reform · References to the Conceptual Framework for Financial Reporting issued on 29 March 2018

Effect of COVID-19 Pandemic

Effect of COVID-19 Pandemic	9 Months Ended
	Sep. 30, 2020
Effect of COVID-19 Pandemic
Effect of COVID-19 Pandemic	3 Effect of COVID-19 Pandemic The COVID-19 pandemic, which began in December 2019, has spread worldwide and continues to cause many governments to maintain measures to slow the spread of the outbreak through quarantines, travel restrictions, closures of borders and requiring maintenance of physical distance between individuals. Due to the complexity of the overall factors, which cannot be reliably separated from unrelated drivers of changes in the Group’s financial performance, the impact of the pandemic could not be quantified. For more information, also refer to note 2.1 COVID-19 reporting and to notes 4 and 5 below on the new COVID-19 segment.

Revenues from contracts with cu

Revenues from contracts with customers	9 Months Ended
	Sep. 30, 2020
Revenues from contracts with customers
Revenues from contracts with customers	4 Revenues from contracts with customers Three months ended September 30 in EUR k Three Months Ended September 30, 2019 Pharmaceutical Diagnostics Total Rendering of services 4,512 6,805 11,317 Sales of goods 321 — 321 Total Revenues from contracts with external customers 4,833 6,805 11,638 Recognized over time 4,512 6,805 11,317 Recognized at a point in time 321 — 321 Total Revenues from contracts with external customers 4,833 6,805 11,638 Geographical information Europe 18 1,945 1,963 —Germany* 18 78 96 Middle East — 3,407 3,407 —Saudi Arabia# — 1,921 1,921 North America 4,815 325 5,140 —United States# 4,815 307 5,122 Latin America — 829 829 Asia Pacific — 299 299 Total Revenues from contracts with external customers 4,833 6,805 11,638 * country of the incorporation of Centogene GmbH # countries contributing more than 10% of the Group’s total consolidated revenues for the three months ended September 30, 2019 in EUR k Three Months Ended September 30, 2020 Pharmaceutical Diagnostics Covid-19 Total Rendering of services 3,598 5,069 26,795 35,462 Sales of goods 202 — 641 843 Total Revenues from contracts with external customers 3,800 5,069 27,436 36,305 Recognized over time 3,598 5,069 8,693 17,360 Recognized at a point in time 202 — 18,743 18,945 Total Revenues from contracts with external customers 3,800 5,069 27,436 36,305 Geographical information Europe 39 1,547 27,238 28,824 —Germany*# 20 52 26,568 26,640 — Netherlands** — — 2 2 Middle East 26 2,648 — 2,674 North America 3,735 333 197 4,265 —United States# 3,735 299 197 4,231 Latin America — 398 1 399 Asia Pacific — 143 — 143 Total Revenues from contracts with external customers 3,800 5,069 27,436 36,305 * country of the incorporation of Centogene GmbH ** country of the incorporation of Centogene N.V. # countries contributing more than 10% of the Group’s total consolidated revenues for the three months ended September 30, 2020 Nine months ended September 30 in EUR k Nine months ended September 30, 2019 Pharmaceutical Diagnostics Total Rendering of services 12,545 20,028 32,573 Sales of goods 986 — 986 Total Revenues from contracts with external customers 13,531 20,028 33,559 Recognized over time 11,964 20,028 31,992 Recognized at a point in time 1,567 — 1,567 Total Revenues from contracts with external customers 13,531 20,028 33,559 Geographical information Europe 298 5,357 5,655 —Germany* 213 211 424 Middle East 61 10,117 10,178 —Saudi Arabia# — 5,102 5,102 North America 13,172 1,646 14,818 —United States# 13,172 1,280 14,452 Latin America — 2,148 2,148 Asia Pacific — 760 760 Total Revenues from contracts with external customers 13,531 20,028 33,559 * country of the incorporation of Centogene GmbH # countries contributing more than 10% of the Group's total consolidated revenues for the nine months ended September 30, 2019 in EUR k Nine months ended September 30, 2020 Pharmaceutical Diagnostics Covid-19 Total Rendering of services 11,478 16,308 28,848 56,634 Sales of goods 812 — 683 1,495 Total Revenues from contracts with external customers 12,290 16,308 29,531 58,129 Recognized over time 11,478 16,308 9,215 37,001 Recognized at a point in time 812 — 20,316 21,128 Total Revenues from contracts with external customers 12,290 16,308 29,531 58,129 Geographical information Europe 106 4,282 29,323 33,711 —Germany*# 58 144 28,645 28,847 — Netherlands** — 3 2 5 Middle East 74 8,852 — 8,926 North America 12,110 1,446 206 13,762 —United States# 12,110 1,254 206 13,570 Latin America — 1,362 2 1,364 Asia Pacific — 366 — 366 Total Revenues from contracts with external customers 12,290 16,308 29,531 58,129 * country of the incorporation of Centogene GmbH ** country of the incorporation of Centogene N.V. # countries contributing more than 10% of the Group's total consolidated revenues for the nine months ended September 30, 2020 The Group collaborated with the majority of our pharmaceutical partners on a worldwide basis in 2019 and 2020. In addition, in cases where our pharmaceutical partners are developing a new rare disease treatment, it is generally anticipated that the final approved treatment will be made available globally. As a result, we allocate the revenues of our pharmaceutical segment by geographical region by reference to the location where each pharmaceutical partner mainly operates, which is based on the region from which most of their revenues are generated. The allocation of revenues in our diagnostics segment and COVID-19 segments are based on the location of each customer. Pharmaceutical segment During the three and nine months ended September 30, 2020, revenues from one pharmaceutical partner represented 7.3% and 14.4% respectively, of the Group's total revenues (the three and nine months ended September 30, 2019: 25.4% and 26.5%, respectively). During the nine months ended September 30, 2019, we have entered into two collaborations with an existing pharmaceutical partner, of which upfront fees of EUR 430k, representing the transaction price allocated to the one-off transfer of the Group's intellectual property, were received and recognized as revenues. No such revenues were recognized in the three and nine months ended September 30, 2020 and the three months ended September 30, 2019. Covid-19 segment The Company has commenced testing for COVID-19 in March 2020. Starting from the Mecklenburg-Western Pomerania region of Germany focusing on employees and essential workers in Rostock, the testing for COVID-19 was further expanded to nursing homes as well as to high school students in Germany, and made available to the rest of the world in May 2020. Some of the tests are offered free of charge by the Company, while others are offered in collaboration with the state government, educational institutions and other companies, as well as via the online marketplace. In particular we expanded our COVID-19 testing and entered into new collaborations during the third quarter by launching a CE-labelled CentoSwab (a two-component dry plastic swab for oropharyngeal swab sampling), and opened test centers at Hamburg Airport, Düsseldorf Airport, the Free State of Bavaria and Munich and Nuremberg Central Stations. COVID-19 revenues are based on a negotiated price per test or on the basis of agreements covering tests to be performed over defined periods. Given the short turnaround time for the COVID-19 tests, revenues from COVID-19 tests that are on a price per test basis are considered as recognized at a point in time. Revenues from COVID-19 tests that are on the basis of agreements covering tests to be performed over defined periods are considered as recognized over time. During the three and nine months ended September 30, 2020, revenues from two COVID-19 partners represented 25.4% and 23.9% for the quarter and 15.9% and 15.0% for the nine months ended, respectively, of the Group’s total revenues. To support the expansion of test offerings, the Company acquired laboratory facilities and equipment, developed a Corona Test Portal and leased laboratory space at several locations in Germany. Additionally, COVID-19 testing capacity is provided through our custom-built CentoTruck, a mobile laboratory in a container setup to carry out the COVID-19 analysis. Total investments in COVID-19 testing as of September 30, 2020 amounted to approximately € 6.3 million, of which approximately € 4.8 million and €0.6 million, respectively, are included in property, plant and equipment and right-of-use assets. An amount of € 0.9 million is included in intangible assets and relates to the development of the Corona Test Portal.

Segment information

Segment information	9 Months Ended
	Sep. 30, 2020
Segment information
Segment information	5 Segment information Three months ended September 30 in EUR k Three months ended September 30, 2019 Pharmaceutical Diagnostics Corporate Total Total Revenues from contracts with external customers 4,833 6,805 — 11,638 Adjusted EBITDA 3,400 757 (4,917) (760) Capital Expenditures Additions to property, plant and equipment and right-of-use assets — 150 276 426 Additions to intangible assets 1,672 — 578 2,250 Other segment information Depreciation and amortization 281 542 789 1,612 Research and development expenses — — 2,011 2,011 in EUR k Three months ended September 30, 2020 Pharmaceutical Diagnostics Covid-19 Corporate Total Total Revenues from contracts with external customers 3,800 5,070 27,435 — 36,305 Adjusted EBITDA 871 (1,210) 9,516 (10,261) (1,084) Capital Expenditures Additions to property, plant and equipment and right-of-use assets 3 195 2,900 516 3,614 Additions to intangible assets 218 — 361 237 816 Other segment information Depreciation and amortization 617 650 110 1,134 2,511 Research and development expenses — — — 4,796 4,796 Nine months ended September 30 Nine Months Ended September 30, 2019 in EUR k Pharmaceutical Diagnostics Corporate Total Total Revenues from contracts with external customers 13,531 20,028 — 33,559 Adjusted EBITDA 9,561 1,298 (14,922) (4,063) Capital Expenditures Additions to property, plant and equipment and right-of-use assets 179 419 668 1,266 Additions to intangible assets 3,458 — 1,908 5,366 Other segment information Depreciation and amortization 794 1,627 2,040 4,461 Research and development expenses — — 6,119 6,119 Nine Months Ended September 30, 2020 in EUR k Pharmaceutical Diagnostics Covid-19 Corporate Total Total Revenues from contracts with external customers 12,290 16,309 29,530 — 58,129 Adjusted EBITDA 5,278 (2,736) 10,306 (26,369) (13,521) Capital Expenditures Additions to property, plant and equipment and right-of-use assets 304 585 5,400 2,352 8,641 Additions to intangible assets 3,072 — 888 821 4,781 Other segment information Depreciation and amortization 1,688 1,757 164 3,334 6,943 Research and development expenses — — — 10,606 10,606 Adjustments Corporate expenses, depreciation and amortization, interest and similar income and expenses, as well as share-based payment expenses are not allocated to individual segments as the underlying instruments are managed on a group basis. Current taxes and deferred taxes are allocated to Corporate as they are also managed on a group basis. Increases in corporate expenses for the three and nine months ended September 30, 2020 are mainly due to our continued international growth and business expansion. The increase is also due to the costs of operating as a public company, such as additional legal, accounting, corporate governance and investor relations expenses, and higher directors' and officers' insurance premiums. Corporate expenses for the three and nine months ended September 30, 2020 included expenses related to the July 2020 Offering as described in note 1 of EUR 105k and EUR 278k, respectively. Corporate expenses for the nine months ended September 30, 2019 also included real estate transfer tax of EUR 1,200k related to an intercompany sale of land and building. No such expenses were incurred in the nine months ended September 30, 2020 (see note 7). Capital expenditure consists of additions of property, plant and equipment, right-of-use assets and intangible assets. All of such assets are located in Germany, which is the country of the registered office of the Company, except for property, plant and equipment of EUR 552k (December 31, 2019: EUR 286k) and right-of-use assets of EUR 792k (December 31, 2019: EUR 1,042k), which is located in the United States. Reconciliation of segment Adjusted EBITDA to Group loss for the period For the three months ended September 30 2019 2020 Reported segment Adjusted EBITDA 4,157 9,177 Corporate expenses (4,917) (10,261) (760) (1,084) Share-based payment expenses (Note 12) (471) (1,149) Depreciation and amortization (1,612) (2,511) Operating loss (2,843) (4,744) Financial costs, net (1,433) (793) Income taxes expenses — (103) Loss for the three months ended September 30 (4,276) (5,640) For the nine months ended September 30 2019 2020 Reported segment Adjusted EBITDA 10,859 12,848 Corporate expenses (14,922) (26,369) (4,063) (13,521) Share-based payment expenses (Note 12) (5,299) (2,542) Depreciation and amortization (4,461) (6,943) Operating loss (13,823) (23,006) Financial costs, net (1,853) (1,498) Income taxes expenses (163) (232) Loss for the nine months ended September 30 (15,839) (24,736)

Other income and expenses

Other income and expenses	9 Months Ended
	Sep. 30, 2020
Other income and expenses
Other income and expenses	6 Other income and expenses 6.1 For the Three months ended September 30 For the Nine months ended September 30 in EUR k 2019 2020 2019 2020 Government grants 363 535 1,833 1,940 Income from the reversal of provisions — — 89 — Gain on disposal of property, plant and equipment 532 — 532 — Others 40 144 169 485 Total other operating income 935 679 2,623 2,425 Government grants contain performance-based grants to subsidize research, development and innovation in the state of Mecklenburg-Western Pomerania from funds granted by the European Regional Development Fund. Furthermore, government grants contain the release of deferred income from investment related grants. 6.2 For the Three months ended September 30 For the Nine months ended September 30 in EUR k 2019 2020 2019 2020 Currency losses — 23 2 60 Others — 30 — 131 Total other operating expenses — 53 2 191 During the nine months ended September 30, 2020, the Group disposed of its entire 51% interest in LPC GmbH (“LPC”) to the minority shareholders for a consideration of EUR 213k, of which EUR 200k is to be paid over a period of four years (and included in other assets, see note 8). The related non-controlling interest of EUR 268k (accumulated share of loss) was debited to profit or loss, and the sale resulted in a loss of EUR 101k.

Sale and Leaseback transaction

Sale and Leaseback transaction	9 Months Ended
	Sep. 30, 2020
Sale and Leaseback transaction
Sale and Leaseback transaction	7 Sale and Leaseback transaction In June 2019, in preparation for a sale and leaseback transaction, the Company sold its land and building (the Rostock headquarters building) with a carrying value of EUR 22,778k to another subsidiary of the Group. Such intercompany transaction resulted in a real estate transfer tax expense of EUR 1,200k and was recognized in the three and nine months period ended September 30, 2019.

Trade receivables and other ass

Trade receivables and other assets	9 Months Ended
	Sep. 30, 2020
Trade receivables and other assets
Trade receivables and other assets	8 Trade receivables and other assets in EUR k Dec 31, 2019 Sep 30, 2020 Non‑current Other assets - Rental deposits 1,948 1,853 Other assets – Others — 100 1,948 1,953 Current Trade receivables, net 12,709 22,674 Contract assets, net 3,884 3,113 Receivables due from shareholders 2,766 — Other assets 5,846 4,055 25,205 29,842 Total non-current and current trade receivables and other assets 27,153 31,795 Trade receivables and contract assets Trade receivables are non-interest bearing and are generally due in 30 to 90 days. In general, portfolio-based expected credit loss allowances are recognized on trade receivables and contract assets. Considering the potential impact of the COVID-19 pandemic on the global economy, the Group has re-assessed the credit loss rates in relation to the outstanding trade receivables and contract assets as follows: in EUR k Dec, 2019 Sep 30, 2020 Not past due 11,102 21,273 Past due 1-30 days 1,113 1,033 Past due 31-90 days 1,708 1,247 Past due more than 90 days 5,005 7,380 Total gross amount of trade receivables and contract assets 18,928 30,933 Expected credit loss rate Not past due 0.3 % 0.7 % Past due 1-30 days 1.0 % 5.9 % Past due 31-90 days 1.2 % 10.1 % Past due more than 90 days 45.4 % 65.3 % Expected credit loss rate on total gross trade receivables and contract assets 12.3 % 16.6 % Expected credit loss 2,335 5,146 Based on the re-assessment the Group recognized impairment losses on receivables and contract assets arising from contracts with customers, included under impairment of financial assets in the consolidated statement of comprehensive loss, amounting to EUR 1,147k and EUR 2,821k, respectively, for the three and nine months ended September 30, 2020 (the three and nine months ended September 30, 2019: EUR 92k and EUR 554k, respectively). Receivables due from shareholders In 2016, the Group established a virtual share option program ("2016 VSOP") under Centogene GmbH that entitled the management board to grant virtual share options to individuals, in regard to services they provide and their continuous commitment to the Group. Upon completion of the IPO in November 2019, all options granted under the 2016 VSOP were vested immediately in full, and the holders of vested options were entitled to receive a direct cash payment from the Company according to the calculation as stipulated in the 2016 VSOP, which is determined based on the IPO price of the shares of Centogene N.V. and the exercise prices of the vested options. The payables by the Group to the holders of vested options were recorded as a liability with a carrying amount of EUR 2,766k by the end of December 31, 2019 (see note 11.2). As the payments to the option holders would be reimbursed by certain original shareholders to the Company, corresponding receivables against shareholders were recorded. Such receivables were considered as additional capital from shareholders and recorded against equity (capital reserve). Upon the completion of the July 2020 Offering, the relevant payables to the holders of vested options were settled by the proceeds received from such original shareholders from the sale of their shares. Other assets The non-current portion of other assets mainly include cash deposit of EUR 1,500k (used to secure a bank guarantee of EUR 3,000k) relating to the leases of Rostock headquarters building, cash deposits of EUR 128k (used to secure a bank guarantee of EUR 257k) relating to the leases of Berlin office and EUR 191k for the leases of certain plant and machineries. It also includes the consideration receivable for the sale of LPC of EUR 200k, among which EUR 100k is due after 1 year (see note 6.2). The current portion of other assets include prepaid expenses of EUR 1,483k (December 31, 2019: EUR 3,481k) as well as receivables from grants of EUR 1,268k (December 31, 2019: EUR 409k).

Cash and short-term deposits

Cash and short-term deposits	9 Months Ended
	Sep. 30, 2020
Cash and short-term deposits
Cash and short term deposits	9 Cash and short‑term deposits As of September 30, 2020, the Group has pledged its short-term deposits with carrying amount of EUR 1,500k (December 31, 2019: EUR 1,500k) and EUR 2,500k (December 31, 2019: EUR 2,500k) respectively, to fulfil collateral requirements in respect of existing secured bank loan and overdraft facility up to EUR 2,500k. In addition, the Group has pledged its short-term deposits of EUR 1,000k (December 31, 2019: EUR nil) related to another overdraft facility up to EUR 500k. The restriction applying to the collateral may be terminated at any time subject to the full amount of the relevant bank loans and the overdrafts being repaid.

Equity

Equity	9 Months Ended
	Sep. 30, 2020
Equity.
Equity	10 Equity As discussed in note 1, Centogene N.V. became the parent holding company of the Group on November 12, 2019 as part of the IPO process. All share, per-share and related information presented in the financial statements and corresponding disclosure notes have been retrospectively adjusted, where applicable, to reflect the impact of the share split resulting from the reorganization. In July 2020, the Company completed a follow-on public offering of 3,500,000 common shares of the Company, consisting of 2,000,000 common shares offered by the Company and 1,500,000 common shares offered by selling shareholders at a price to the public of USD 14.00 per common share (i.e. EUR 12.71 per share). Aggregate offering proceeds, net of underwriting discounts, commissions and transaction costs, were EUR 22 million to the Company. Capital reserve As of September 30, 2020, capital reserve included a share premium of EUR 107,499k, being amounts paid in by shareholders at the issuance of shares in excess of the par value of the shares issued, net of any transaction costs incurred for the share issuance. In addition, it also included amounts recorded in respect of share-based payments. For additional information on the share-based payments, see note 12.

Financial liabilities

Financial liabilities	9 Months Ended
	Sep. 30, 2020
Financial liabilities
Financial liabilities	11 Financial liabilities 11.1 in EUR k Dec 31, 2019 Sep 30, 2020 Non‑current liabilities Non‑current portion of secured bank loans 968 501 Municipal loans 610 — Total non‑current loans 1,578 501 Lease liabilities 18,069 18,052 Total non‑current liabilities 19,647 18,553 Current liabilities Current portion of secured bank loans 802 868 Other bank loans — 406 Bank overdrafts 2,636 3,345 Municipal loans 250 — Total current loans 3,688 4,619 Current portion of lease liabilities 3,635 3,295 Total current liabilities 7,323 7,914 Total non‑current and current liabilities 26,970 26,467 As of September 30, 2020, short-term cash deposits of EUR 1,500k (December 31, 2019: EUR 1,500k) were used to secure the secured bank loan outstanding (see note 9). Other bank loans outstanding as of September 30, 2020 represented bank loans granted under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act). Subject to certain reporting and review requirements, the Company may apply for forgiveness of the amount after the 24-week period beginning on the date of first disbursement of the loans. The Company is in the process of preparing the relevant application and anticipates the result of the forgiveness will be available in the first half of 2021. The amount which is forgiven will be considered as government grant income, while any remaining amount not forgiven will be repaid by the Company. Accordingly, the entire amount was classified as current. The following table is based on the original terms and conditions: Conditions and statement of liabilities The outstanding interest-bearing liabilities as of September 30, 2020 and December 31, 2019 have the following conditions: Dec 31, 2019 Sep 30, 2020 Nominal Carrying Nominal Carrying in EUR k Currency Nominal interest rate Maturity amount amount amount amount Secured bank loan EUR 3.95% 2018‑25 1,770 1,770 1,369 1,369 Other bank loan USD 1% 2020-22 — — 406 406 Municipal loan EUR 8.25%; plus 1.5% profit-related; 0.75% on losses 2018-23 500 500 — — Municipal loan EUR 8%; plus 1.5% profit-related; 0.75% on losses 2021 360 360 — — Bank overdrafts EUR 4.46% Rollover 476 476 490 490 Bank overdrafts EUR 3.75% Rollover 2,160 2,160 2,405 2,405 Bank overdrafts EUR 3.59% Rollover — — 450 450 Lease liabilities EUR 2.1%-3.5%*, 5.4%-8.9% 2017-31 21,704 21,704 21,347 21,347 Total interest‑bearing financial liabilities 26,970 26,970 26,467 26,467 * represents the incremental borrowing rate of the Group at the commencement of the leases The bank overdrafts of EUR 2,405k as of September 30, 2020 (December 31, 2019: EUR 2,160k) were secured by short-term deposits with a carrying amount of EUR 2,500k (December 31, 2019: EUR 2,500k) (see note 9). The bank overdrafts of EUR 490k (December 31, 2019: EUR 476k) were secured by guarantees provided by certain of the Company's shareholders as of December 31, 2019, and these guarantees were released providing security over a short-term deposit with a carrying amount of EUR 500k subsequent to the year end (see note 9). The municipal loan due to MBMV (Mittelständische Bürgschaftsbank Mecklenburg-Vorpommern) of EUR 860k outstanding as of December 31, 2019 was secured by guarantees provided by the Group's shareholders, and were released upon full repayment in February 2020. 11.2 in EUR k Dec 31, 2019 Sep 30, 2020 Trade payables 8,554 12,052 Government grants (deferred income) 11,289 10,646 Liability for Virtual Stock Option Program 2,769 — Contract liabilities 3,748 3,134 Others 5,258 9,866 Trade payables and other liabilities 31,618 35,698 Non‑current 9,941 9,296 Current 21,677 26,402 Government grants mainly include investment-related government grants. These were received for the purchase of certain items of property, plant and equipment for the research and development facilities in Mecklenburg-Western Pomerania, including the Rostock facility. The grants were issued in the form of investment subsidies as part of the joint federal and state program, "Verbesserung der regionalen Wirtschaftsstruktur" (improvement of the regional economic structure) in connection with funds from the European Regional Development Fund. Additional grants received during the nine months ended September 30, 2020 are related to the purchase of certain items of property, plant and equipment amounted to EUR 390k (the nine months ended September 30, 2019: EUR 341k). In addition, other liabilities include a provision for outstanding invoices of EUR 4,675k (December 31, 2019: EUR 1,210k) which mainly relates to pandemic related invoices, personnel-related liabilities for vacation and bonuses totaling EUR 2,662k (December 31, 2019: EUR 2,264k), a VAT payable of EUR 963k (December 31, 2019: EUR 1,311k receivable), as well as liabilities for wage and church tax of EUR 478k (December 31, 2019: EUR 376k). Other liabilities as of September 30, 2020 do not include costs related to the July 2020 Offering, while other liabilities as of December 31, 2019 included costs relating to the IPO of EUR 565k.

Share-based payments

Share-based payments	9 Months Ended
	Sep. 30, 2020
Share-based payments
Share-based payments	12 Share‑based payments At September 30, 2020 the Group had the following share‑based payment arrangements. (i) Equity share option - Replacement (ESOP 2017) In 2017, the Group established a second virtual share option program ("2017 VSOP”) that entitled the management board to grant virtual share options to individuals, in regard to services they provide and their continuous commitment to the Group. For the nine months ended September 30, 2019, the Group recognized EUR 5,299k of share-based payment expense in the statement of comprehensive income in relation to the cash-settled virtual share option programs of Centogene GmbH, which were cancelled upon completion of IPO. In connection with the IPO (see note 1), a transfer agreement was entered into between the holders of the 2017 VSOP, Centogene GmbH and the Company in November 2019, under which the 2017 VSOP was terminated, and the option holders were granted new share options of Centogene N.V. (“ESOP 2017”). This transaction was accounted for as a replacement, no incremental fair value arose on this transaction. The number of options granted to each holder under ESOP 2017 was based on the number of options granted to them under 2017 VSOP and the IPO price of Centogene N.V. Accordingly, 805,308 new share options were granted pursuant to Centogene N.V’s long-term incentive plan (the “Long-term Incentive Plan”), with each option representing one common share of Centogene N.V., and an exercise price equal to the nominal value of the share of Centogene N.V., which is EUR 0.12. The options were considered vested upon the completion of the IPO, but were not exercisable in the first 180 days subsequent to the listing (lock-up period). The remaining contractual life for the share options as at September 30, 2020 is 9.25 years (December 31, 2019: 10 years). The share options issued under ESOP 2017 are equity-settled and the fair value of the options were fully recognized in equity under capital reserve on the date of grant, i.e. at the replacement date. (ii) Equity share option 2019 (ESOP 2019) In 2019, an agreement was entered into between the Company and an individual of the Supervisory Board. According to this agreement, a total of 396,522 options, each option representing one common share, were granted pursuant to the Long-term Incentive Plan to the individual Supervisory Board member with exercise price equaling to the IPO price, which is EUR 12.58 per option, on the date of the IPO of the Company. The vesting period shall be three years commencing on the day of grant, where one-third of the granted options shall be vested at the end of each year of grant, and the first year ending on March 31, 2020. The contractual life for the share options as at December 31, 2019 is ten years and the weighted average fair value of options outstanding was EUR 9.08. The share options issued under “ESOP 2019” will be equity-settled and the fair value of the options were recognized in equity under capital reserve, based on the fair value on the date of grant, and will be charged to profit or loss over the vesting period by using the graded vested approach. For the three and nine months ended September 30, 2020, the Group recognized EUR 336k and EUR 1,728k respectively, of share-based payment expense in the statement of comprehensive income. (iii) Long-Term Incentive Plan (LTIP) In 2019, the Company established a Long-Term Incentive Plan (“LTIP”) that entitled the Supervisory Board or the Management Board, as applicable, to grant share-based awards to members of the Supervisory Board, members of the Management Board, employees, officers and certain other service providers. Under the LTIP, the maximum number of shares underlying awards made under the LTIP (excluding awards granted in replacement of other awards in connection with an acquisition, merger or business combination) shall not exceed 13% of the Company’s issued share capital immediately following the completion of the initial public offering of the Company's ordinary shares, provided that, on January 1, 2020 and on January 1 of each calendar year thereafter, such maximum number shall be increased with an additional number of shares equal to 3% of the Company’s issued share capital on such date (or any lower number of Shares as determined by the Supervisory Board). Effective as of September 11, 2020, the Supervisory Board granted members of the Management Board the following options and restricted stock units ("RSUs") under the LTIP: a. to the Company’s Chief Executive Officer: 36,175 Options and 72,350 RSUs; b. to the Company’s Chief Financial Officer: 16,250 Options and 32,250 RSUs; and c. to the Company’s Chief Information Officer: 15,000 Options and 30,000 RSUs. Effective as of September 11, 2020, the Management Board granted 87,500 options and 75,000 RSUs to other key current and former executive officers. Apart from one award that immediately vested in full on the grant date and another award that vests in three equal tranches on each anniversary of its date of first employment, all other awards referred to above shall vest in three equal tranches from January 1 following the grant date, in accordance with the following vesting schedule: i. one third of the awards vest on January 1, 2021; ii. one third of the awards vest on January 1, 2022; and iii. one third of the awards vest on January 1, 2023. All of the foregoing awards vest in full upon the occurrence of a change of control as defined by the LTIP, unless the holder is no longer eligible to participate in the LTIP at that time. The options referred to above vest only if the 20-trading day volume-weighted average stock price of the Company's shares preceding the vesting date of each tranche exceeds the exercise price of USD 11.60. This hurdle is considered a market condition. Therefore, expenses would not be reversed, if the tranches do not ultimately vest. The RSUs referred to above have no performance-based vesting criteria. RSUs represent a right to receive a payment equal to the value of the RSU at the exercise date. The company has a choice to settle either in cash, in shares or a combination thereof. In line with this policy both types of awards are to be settled in shares and expire on the 10 th anniversary of the grant date. The fair value of the options as of the grant date was determined using a Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple input variables to estimate the probability that market conditions will be achieved. The input variables include stock price volatility of 75% based on other public companies in the relevant industry, and risk-free interest rate of 0.8% to estimate the probability of satisfying the market conditions and the resulting fair value of the award. For the three and nine months ended September 30, 2020, the Company recognized EUR 812k of share-based payment expenses in the statement of comprehensive income in relation to these awards under the LTIP plan.

Commitments

Commitments	9 Months Ended
	Sep. 30, 2020
Commitments
Commitments	13 Commitments Future payments for non-cancellable leases The Group has various lease contracts in relation to the expansion of the Rostock headquarters and leasing of the Frankfurt laboratory, Airport Berlin, Airport Düsseldorf, Airport Frankfurt and additional laboratory space in Hamburg. The future lease payments and utilities for these non-cancellable lease contracts are EUR 380k within one year, EUR 1,838k within five years and EUR 5,012k thereafter (December 31, 2019: EUR nil). The Group has various non-cancellable lease contracts of office equipment and storage spaces which had a lease term of less than 12 months or were related to leases of low-value assets, and therefore the short-term lease recognition exemption was applied to these contracts. The future lease payments for these non-cancellable lease contracts are EUR 75k within one year (December 31,2019: EUR 72k) and EUR 23k within five years (December 31, 2019: EUR 36k). Future payment obligations As of September 30, 2020, the Group concluded agreements with suppliers, for goods and services to be provided subsequent to September 30, 2020 with a total payment obligation of approximately EUR 7,131k (December 31, 2019: EUR 802k).

Contingent Liabilities

Contingent Liabilities	9 Months Ended
	Sep. 30, 2020
Contingent Liabilities
Contingent Liabilities	14 Contingent Liabilities In May 2016, the Company was informed in writing by the Universitair Medisch Centrum Utrecht ( ‘‘ UMCU ’’ ) that a claim had been initiated against UMCU regarding a prenatal diagnostic test that the Company conducted at their request which failed to identify a specific mutation present in a patient. On November 8, 2018, the UMCU and Neon Underwriting Limited formally filed a legal claim in the local court in Rostock, Germany against the Company alleging that the Company’s negligence in performing the test resulted in the misdiagnosis of the patient. UMCU is seeking recovery for compensatory damages as a result of the alleged misdiagnosis. By court order of November 8, 2018 the Regional Court of Rostock set the amount in dispute at EUR 880k. On November 12, 2018, the Company submitted a notice to the Regional Court of Rostock of the intention to defend against the claim. On January 3, 2019, the Company filed a motion to dismiss in which the Company denied the merits of the claim. UMCU and Neon Underwriting Limited responded to this motion on March 15, 2019 with a statement of reply, and the parties made several court filings setting out their arguments since. By order dated June 3, 2019, the Regional Court of Rostock provided a first set of questions to be answered by an expert witness. Following a request by the Court, the Director of the Institute of Genetics at the University of Bonn recommended a professor for human genetics from the University of Aachen be appointed as an expert witness in this case. The Company agreed to such recommendation. As of September 30, 2020, the dispute amount was EUR 1.3 million. The claim was assigned to a new judge, due to an illness of the preceding judge, while the decision to appoint the recommended expert witness has not yet been finalized. The Company intends to continue to rigorously defend its position and considers that it is not probable the legal claim towards the Company will be successful and as a result has not recognized a provision for this claim as of September 30, 2020. In addition, in case a settlement would be required, the Company believes that the corresponding liability will be fully covered by the respective existing insurance policies. The higher regional court of Rostock issued a final decision by which it renders a contract entered into between the State of Mecklenburg-Western Pomerania (“MVP”) and the Company for Corona testing as invalid with retroactive effect under a public procurement litigation case. Under this contract, the Company has invoiced and received a total amount of EUR 2.3 million. Since the contract was rendered invalid, MVP now has a claim under German law against the Company for repayment of the full amount invoiced and received. The Company at the same time has a claim against MVP for compensation for the value of services provided in expectation of the validity of the contract. In the typical scenario, the amounts of these two claims would equal each other and could be offset against each other. However, there can be no assurance that MVP will take the view that the amount of its claim equals and offsets the amount of the Company’s claim. To the extent MVP’s claim exceeds the Company’s claim against MVP, Centogene may ultimately have a payment obligation, which could materially adversely affect the Group’s financial position and results of operations.

Subsequent Event

Subsequent Event	9 Months Ended
	Sep. 30, 2020
Subsequent Event
Subsequent Event	15 Subsequent Events Leadership transition On October 20, 2020 the Company announced that Prof. Arndt Rolfs, the Company’s founder and former Chief Executive Officer (CEO), has decided to step down as CEO of Centogene as of October 20, 2020, and that Andrin Oswald, M.D., will join the Company as CEO effective December 1, 2020. Prof. Rolfs has agreed to serve as an advisor during the transition period until December 31, 2020. The financial impact of the departure of Prof. Rolfs, in the fourth quarter of 2020, are additional expenses relating to one full year’s base salary aggregating to EUR 565k, as well as additional share-based payment expenses of EUR 162k and EUR 620k respectively relating to all LTIP options and RSUs granted in 2020 that would vest immediately. LTIP grant of restricted stock units In October 2020, 251,500 RSUs granted to employees were issued, subject to the terms of the LTIP, the applicable award agreement and the terms specified in the authorization from the Supervisory Board for this purpose. The awards will vest in three equal tranches over a three-year period from January 1, 2021 to January 1, 2023.

Revenues from contracts with _2

Revenues from contracts with customers (Tables)	9 Months Ended
	Sep. 30, 2020
Revenues from contracts with customers
Schedule of geographical information	in EUR k Three Months Ended September 30, 2019 Pharmaceutical Diagnostics Total Rendering of services 4,512 6,805 11,317 Sales of goods 321 — 321 Total Revenues from contracts with external customers 4,833 6,805 11,638 Recognized over time 4,512 6,805 11,317 Recognized at a point in time 321 — 321 Total Revenues from contracts with external customers 4,833 6,805 11,638 Geographical information Europe 18 1,945 1,963 —Germany* 18 78 96 Middle East — 3,407 3,407 —Saudi Arabia# — 1,921 1,921 North America 4,815 325 5,140 —United States# 4,815 307 5,122 Latin America — 829 829 Asia Pacific — 299 299 Total Revenues from contracts with external customers 4,833 6,805 11,638 * country of the incorporation of Centogene GmbH # countries contributing more than 10% of the Group’s total consolidated revenues for the three months ended September 30, 2019 in EUR k Three Months Ended September 30, 2020 Pharmaceutical Diagnostics Covid-19 Total Rendering of services 3,598 5,069 26,795 35,462 Sales of goods 202 — 641 843 Total Revenues from contracts with external customers 3,800 5,069 27,436 36,305 Recognized over time 3,598 5,069 8,693 17,360 Recognized at a point in time 202 — 18,743 18,945 Total Revenues from contracts with external customers 3,800 5,069 27,436 36,305 Geographical information Europe 39 1,547 27,238 28,824 —Germany*# 20 52 26,568 26,640 — Netherlands** — — 2 2 Middle East 26 2,648 — 2,674 North America 3,735 333 197 4,265 —United States# 3,735 299 197 4,231 Latin America — 398 1 399 Asia Pacific — 143 — 143 Total Revenues from contracts with external customers 3,800 5,069 27,436 36,305 * country of the incorporation of Centogene GmbH ** country of the incorporation of Centogene N.V. # countries contributing more than 10% of the Group’s total consolidated revenues for the three months ended September 30, 2020 Nine months ended September 30 in EUR k Nine months ended September 30, 2019 Pharmaceutical Diagnostics Total Rendering of services 12,545 20,028 32,573 Sales of goods 986 — 986 Total Revenues from contracts with external customers 13,531 20,028 33,559 Recognized over time 11,964 20,028 31,992 Recognized at a point in time 1,567 — 1,567 Total Revenues from contracts with external customers 13,531 20,028 33,559 Geographical information Europe 298 5,357 5,655 —Germany* 213 211 424 Middle East 61 10,117 10,178 —Saudi Arabia# — 5,102 5,102 North America 13,172 1,646 14,818 —United States# 13,172 1,280 14,452 Latin America — 2,148 2,148 Asia Pacific — 760 760 Total Revenues from contracts with external customers 13,531 20,028 33,559 * country of the incorporation of Centogene GmbH # countries contributing more than 10% of the Group's total consolidated revenues for the nine months ended September 30, 2019 in EUR k Nine months ended September 30, 2020 Pharmaceutical Diagnostics Covid-19 Total Rendering of services 11,478 16,308 28,848 56,634 Sales of goods 812 — 683 1,495 Total Revenues from contracts with external customers 12,290 16,308 29,531 58,129 Recognized over time 11,478 16,308 9,215 37,001 Recognized at a point in time 812 — 20,316 21,128 Total Revenues from contracts with external customers 12,290 16,308 29,531 58,129 Geographical information Europe 106 4,282 29,323 33,711 —Germany*# 58 144 28,645 28,847 — Netherlands** — 3 2 5 Middle East 74 8,852 — 8,926 North America 12,110 1,446 206 13,762 —United States# 12,110 1,254 206 13,570 Latin America — 1,362 2 1,364 Asia Pacific — 366 — 366 Total Revenues from contracts with external customers 12,290 16,308 29,531 58,129 * country of the incorporation of Centogene GmbH ** country of the incorporation of Centogene N.V. # countries contributing more than 10% of the Group's total consolidated revenues for the nine months ended September 30, 2020

Segment information (Tables)

Segment information (Tables)	9 Months Ended
	Sep. 30, 2020
Segment information
Schedule of segment information and reconciliation of segment adjusted EBITDA to group loss for the period	Three months ended September 30 in EUR k Three months ended September 30, 2019 Pharmaceutical Diagnostics Corporate Total Total Revenues from contracts with external customers 4,833 6,805 — 11,638 Adjusted EBITDA 3,400 757 (4,917) (760) Capital Expenditures Additions to property, plant and equipment and right-of-use assets — 150 276 426 Additions to intangible assets 1,672 — 578 2,250 Other segment information Depreciation and amortization 281 542 789 1,612 Research and development expenses — — 2,011 2,011 in EUR k Three months ended September 30, 2020 Pharmaceutical Diagnostics Covid-19 Corporate Total Total Revenues from contracts with external customers 3,800 5,070 27,435 — 36,305 Adjusted EBITDA 871 (1,210) 9,516 (10,261) (1,084) Capital Expenditures Additions to property, plant and equipment and right-of-use assets 3 195 2,900 516 3,614 Additions to intangible assets 218 — 361 237 816 Other segment information Depreciation and amortization 617 650 110 1,134 2,511 Research and development expenses — — — 4,796 4,796 Nine months ended September 30 Nine Months Ended September 30, 2019 in EUR k Pharmaceutical Diagnostics Corporate Total Total Revenues from contracts with external customers 13,531 20,028 — 33,559 Adjusted EBITDA 9,561 1,298 (14,922) (4,063) Capital Expenditures Additions to property, plant and equipment and right-of-use assets 179 419 668 1,266 Additions to intangible assets 3,458 — 1,908 5,366 Other segment information Depreciation and amortization 794 1,627 2,040 4,461 Research and development expenses — — 6,119 6,119 Nine Months Ended September 30, 2020 in EUR k Pharmaceutical Diagnostics Covid-19 Corporate Total Total Revenues from contracts with external customers 12,290 16,309 29,530 — 58,129 Adjusted EBITDA 5,278 (2,736) 10,306 (26,369) (13,521) Capital Expenditures Additions to property, plant and equipment and right-of-use assets 304 585 5,400 2,352 8,641 Additions to intangible assets 3,072 — 888 821 4,781 Other segment information Depreciation and amortization 1,688 1,757 164 3,334 6,943 Research and development expenses — — — 10,606 10,606 Reconciliation of segment Adjusted EBITDA to Group loss for the period For the three months ended September 30 2019 2020 Reported segment Adjusted EBITDA 4,157 9,177 Corporate expenses (4,917) (10,261) (760) (1,084) Share-based payment expenses (Note 12) (471) (1,149) Depreciation and amortization (1,612) (2,511) Operating loss (2,843) (4,744) Financial costs, net (1,433) (793) Income taxes expenses — (103) Loss for the three months ended September 30 (4,276) (5,640) For the nine months ended September 30 2019 2020 Reported segment Adjusted EBITDA 10,859 12,848 Corporate expenses (14,922) (26,369) (4,063) (13,521) Share-based payment expenses (Note 12) (5,299) (2,542) Depreciation and amortization (4,461) (6,943) Operating loss (13,823) (23,006) Financial costs, net (1,853) (1,498) Income taxes expenses (163) (232) Loss for the nine months ended September 30 (15,839) (24,736)

Other income and expenses (Tabl

Other income and expenses (Tables)	9 Months Ended
	Sep. 30, 2020
Other income and expenses
Schedule of other operating income	For the Three months ended September 30 For the Nine months ended September 30 in EUR k 2019 2020 2019 2020 Government grants 363 535 1,833 1,940 Income from the reversal of provisions — — 89 — Gain on disposal of property, plant and equipment 532 — 532 — Others 40 144 169 485 Total other operating income 935 679 2,623 2,425
Schedule of other operating expenses	For the Three months ended September 30 For the Nine months ended September 30 in EUR k 2019 2020 2019 2020 Currency losses — 23 2 60 Others — 30 — 131 Total other operating expenses — 53 2 191

Trade receivables and other a_2

Trade receivables and other assets (Tables)	9 Months Ended
	Sep. 30, 2020
Trade receivables and other assets
Summary of trade receivables and other assets	in EUR k Dec 31, 2019 Sep 30, 2020 Non‑current Other assets - Rental deposits 1,948 1,853 Other assets – Others — 100 1,948 1,953 Current Trade receivables, net 12,709 22,674 Contract assets, net 3,884 3,113 Receivables due from shareholders 2,766 — Other assets 5,846 4,055 25,205 29,842 Total non-current and current trade receivables and other assets 27,153 31,795
Summary of expected credit loss rate on total gross trade receivables and contract assets	in EUR k Dec, 2019 Sep 30, 2020 Not past due 11,102 21,273 Past due 1-30 days 1,113 1,033 Past due 31-90 days 1,708 1,247 Past due more than 90 days 5,005 7,380 Total gross amount of trade receivables and contract assets 18,928 30,933 Expected credit loss rate Not past due 0.3 % 0.7 % Past due 1-30 days 1.0 % 5.9 % Past due 31-90 days 1.2 % 10.1 % Past due more than 90 days 45.4 % 65.3 % Expected credit loss rate on total gross trade receivables and contract assets 12.3 % 16.6 % Expected credit loss 2,335 5,146

Financial liabilities (Tables)

Financial liabilities (Tables)	9 Months Ended
	Sep. 30, 2020
Financial liabilities
Schedule of interest-bearing liabilities	in EUR k Dec 31, 2019 Sep 30, 2020 Non‑current liabilities Non‑current portion of secured bank loans 968 501 Municipal loans 610 — Total non‑current loans 1,578 501 Lease liabilities 18,069 18,052 Total non‑current liabilities 19,647 18,553 Current liabilities Current portion of secured bank loans 802 868 Other bank loans — 406 Bank overdrafts 2,636 3,345 Municipal loans 250 — Total current loans 3,688 4,619 Current portion of lease liabilities 3,635 3,295 Total current liabilities 7,323 7,914 Total non‑current and current liabilities 26,970 26,467
Schedule of outstanding interest-bearing liabilities	Dec 31, 2019 Sep 30, 2020 Nominal Carrying Nominal Carrying in EUR k Currency Nominal interest rate Maturity amount amount amount amount Secured bank loan EUR 3.95% 2018‑25 1,770 1,770 1,369 1,369 Other bank loan USD 1% 2020-22 — — 406 406 Municipal loan EUR 8.25%; plus 1.5% profit-related; 0.75% on losses 2018-23 500 500 — — Municipal loan EUR 8%; plus 1.5% profit-related; 0.75% on losses 2021 360 360 — — Bank overdrafts EUR 4.46% Rollover 476 476 490 490 Bank overdrafts EUR 3.75% Rollover 2,160 2,160 2,405 2,405 Bank overdrafts EUR 3.59% Rollover — — 450 450 Lease liabilities EUR 2.1%-3.5%*, 5.4%-8.9% 2017-31 21,704 21,704 21,347 21,347 Total interest‑bearing financial liabilities 26,970 26,970 26,467 26,467 * represents the incremental borrowing rate of the Group at the commencement of the leases
Schedule of trade payables and other liabilities	in EUR k Dec 31, 2019 Sep 30, 2020 Trade payables 8,554 12,052 Government grants (deferred income) 11,289 10,646 Liability for Virtual Stock Option Program 2,769 — Contract liabilities 3,748 3,134 Others 5,258 9,866 Trade payables and other liabilities 31,618 35,698 Non‑current 9,941 9,296 Current 21,677 26,402

General company information (De

General company information (Details) - 1 months ended Jul. 31, 2020 - Follow-on public offering - Common shares - Major purchases of assets € / shares in Units, € in Millions	$ / shares	EUR (€)€ / sharesshares
General company information
Number of common shares issued (in shares)		3,500,000
Public offering price (in dollars per share) | (per share)	$ 14	€ 12.71
Selling shareholders
General company information
Number of common shares issued (in shares)		1,500,000
The Company
General company information
Number of common shares issued (in shares)		2,000,000
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs | €		€ 22

Revenues from contracts with _3

Revenues from contracts with customers - Geographical information (Details) - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Disclosure of geographical areas
Rendering of services	€ 35,462	€ 11,317	€ 56,634	€ 32,573
Sales of goods	843	321	1,495	986
Total Revenues from contracts with external customers	36,305	11,638	58,129	33,559
Europe
Disclosure of geographical areas
Total Revenues from contracts with external customers	28,824	1,963	33,711	5,655
Germany
Disclosure of geographical areas
Total Revenues from contracts with external customers	26,640	96	28,847	424
-Netherlands
Disclosure of geographical areas
Total Revenues from contracts with external customers	2		5
Middle East
Disclosure of geographical areas
Total Revenues from contracts with external customers	2,674	3,407	8,926	10,178
-Saudi Arabia
Disclosure of geographical areas
Total Revenues from contracts with external customers		1,921		5,102
North America
Disclosure of geographical areas
Total Revenues from contracts with external customers	4,265	5,140	13,762	14,818
-United States
Disclosure of geographical areas
Total Revenues from contracts with external customers	4,231	5,122	13,570	14,452
Latin America
Disclosure of geographical areas
Total Revenues from contracts with external customers	399	829	1,364	2,148
Asia Pacific
Disclosure of geographical areas
Total Revenues from contracts with external customers	143	299	366	760
Recognized over time
Disclosure of geographical areas
Total Revenues from contracts with external customers	17,360	11,317	37,001	31,992
Recognized at a point in time
Disclosure of geographical areas
Total Revenues from contracts with external customers	18,945	321	21,128	1,567
Pharmaceutical
Disclosure of geographical areas
Rendering of services	3,598	4,512	11,478	12,545
Sales of goods	202	321	812	986
Total Revenues from contracts with external customers	3,800	4,833	12,290	13,531
Pharmaceutical | Europe
Disclosure of geographical areas
Total Revenues from contracts with external customers	39	18	106	298
Pharmaceutical | Germany
Disclosure of geographical areas
Total Revenues from contracts with external customers	20	18	58	213
Pharmaceutical | -Netherlands
Disclosure of geographical areas
Total Revenues from contracts with external customers	0
Pharmaceutical | Middle East
Disclosure of geographical areas
Total Revenues from contracts with external customers	26		74	61
Pharmaceutical | North America
Disclosure of geographical areas
Total Revenues from contracts with external customers	3,735	4,815	12,110	13,172
Pharmaceutical | -United States
Disclosure of geographical areas
Total Revenues from contracts with external customers	3,735	4,815	12,110	13,172
Pharmaceutical | Recognized over time
Disclosure of geographical areas
Total Revenues from contracts with external customers	3,598	4,512	11,478	11,964
Pharmaceutical | Recognized at a point in time
Disclosure of geographical areas
Total Revenues from contracts with external customers	202	321	812	1,567
Diagnostics
Disclosure of geographical areas
Rendering of services	5,069	6,805	16,308	20,028
Total Revenues from contracts with external customers	5,069	6,805	16,308	20,028
Diagnostics | Europe
Disclosure of geographical areas
Total Revenues from contracts with external customers	1,547	1,945	4,282	5,357
Diagnostics | Germany
Disclosure of geographical areas
Total Revenues from contracts with external customers	52	78	144	211
Diagnostics | -Netherlands
Disclosure of geographical areas
Total Revenues from contracts with external customers	0		3
Diagnostics | Middle East
Disclosure of geographical areas
Total Revenues from contracts with external customers	2,648	3,407	8,852	10,117
Diagnostics | -Saudi Arabia
Disclosure of geographical areas
Total Revenues from contracts with external customers		1,921		5,102
Diagnostics | North America
Disclosure of geographical areas
Total Revenues from contracts with external customers	333	325	1,446	1,646
Diagnostics | -United States
Disclosure of geographical areas
Total Revenues from contracts with external customers	299	307	1,254	1,280
Diagnostics | Latin America
Disclosure of geographical areas
Total Revenues from contracts with external customers	398	829	1,362	2,148
Diagnostics | Asia Pacific
Disclosure of geographical areas
Total Revenues from contracts with external customers	143	299	366	760
Diagnostics | Recognized over time
Disclosure of geographical areas
Total Revenues from contracts with external customers	5,069	€ 6,805	16,308	€ 20,028
Covid-19
Disclosure of geographical areas
Rendering of services	26,795		28,848
Sales of goods	641		683
Total Revenues from contracts with external customers	27,436		29,531
Covid-19 | Europe
Disclosure of geographical areas
Total Revenues from contracts with external customers	27,238		29,323
Covid-19 | Germany
Disclosure of geographical areas
Total Revenues from contracts with external customers	26,568		28,645
Covid-19 | -Netherlands
Disclosure of geographical areas
Total Revenues from contracts with external customers	2		2
Covid-19 | North America
Disclosure of geographical areas
Total Revenues from contracts with external customers	197		206
Covid-19 | -United States
Disclosure of geographical areas
Total Revenues from contracts with external customers	197		206
Covid-19 | Latin America
Disclosure of geographical areas
Total Revenues from contracts with external customers	1		2
Covid-19 | Recognized over time
Disclosure of geographical areas
Total Revenues from contracts with external customers	8,693		9,215
Covid-19 | Recognized at a point in time
Disclosure of geographical areas
Total Revenues from contracts with external customers	€ 18,743		€ 20,316

Revenue from contracts with cus

Revenue from contracts with customers - Additional Information (Details) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020EUR (€)customer	Sep. 30, 2019EUR (€)	Sep. 30, 2020EUR (€)customer	Sep. 30, 2019EUR (€)
Revenue from contracts with customers
Revenue from contracts with customers	€ 36,305	€ 11,638	€ 58,129	€ 33,559
Investment in COVID-19 testing	6,300		6,300
Investment in COVID-19 testing, included in PP&E	4,800		4,800
Investment in COVID-19 testing, included in right-of-use assets	600		600
Investment in Corona Test Portal, included in intangible assets	€ 900		€ 900
Pharmaceutical Partner
Revenue from contracts with customers
Number of customer in group | customer	1		1
Revenue contributed as a percentage of Group's total revenues	7.30%	25.40%	14.40%	26.50%
Revenue from contracts with customers	€ 0	€ 0	€ 0	€ 430
Covid-19 Partner One
Revenue from contracts with customers
Revenue contributed as a percentage of Group's total revenues	25.40%		15.90%
Covid-19 Partner Two
Revenue from contracts with customers
Revenue contributed as a percentage of Group's total revenues	23.90%		15.00%

Segment information - Informati

Segment information - Information by operating segments (Details) - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Segment information
Rendering of services	€ 35,462	€ 11,317	€ 56,634	€ 32,573
Sales of goods	843	321	1,495	986
Total Revenues from contracts with external customers	36,305	11,638	58,129	33,559
Adjusted EBITDA	(1,084)	(760)	(13,521)	(4,063)
Additions to property, plant and equipment and right-of-use assets	3,614	426	8,641	1,266
Additions to intangible assets	816	2,250	4,781	5,366
Other segment information
Depreciation and amortization	2,511	1,612	6,943	4,461
Research and development expenses	4,796	2,011	10,606	6,119
Pharmaceutical
Segment information
Rendering of services	3,598	4,512	11,478	12,545
Sales of goods	202	321	812	986
Total Revenues from contracts with external customers	3,800	4,833	12,290	13,531
Diagnostics
Segment information
Rendering of services	5,069	6,805	16,308	20,028
Total Revenues from contracts with external customers	5,069	6,805	16,308	20,028
Covid-19
Segment information
Rendering of services	26,795		28,848
Sales of goods	641		683
Total Revenues from contracts with external customers	27,436		29,531
Operating segment | Pharmaceutical
Segment information
Total Revenues from contracts with external customers	3,800	4,833	12,290	13,531
Adjusted EBITDA	871	3,400	5,278	9,561
Additions to property, plant and equipment and right-of-use assets	3		304	179
Additions to intangible assets	218	1,672	3,072	3,458
Other segment information
Depreciation and amortization	617	281	1,688	794
Operating segment | Diagnostics
Segment information
Total Revenues from contracts with external customers	5,070	6,805	16,309	20,028
Adjusted EBITDA	(1,210)	757	(2,736)	1,298
Additions to property, plant and equipment and right-of-use assets	195	150	585	419
Other segment information
Depreciation and amortization	650	542	1,757	1,627
Operating segment | Covid-19
Segment information
Total Revenues from contracts with external customers	27,435		29,530
Adjusted EBITDA	9,516		10,306
Additions to property, plant and equipment and right-of-use assets	2,900		5,400
Additions to intangible assets	361		888
Other segment information
Depreciation and amortization	110		164
Corporate
Segment information
Adjusted EBITDA	(10,261)	(4,917)	(26,369)	(14,922)
Additions to property, plant and equipment and right-of-use assets	516	276	2,352	668
Additions to intangible assets	237	578	821	1,908
Other segment information
Depreciation and amortization	1,134	789	3,334	2,040
Research and development expenses	€ 4,796	€ 2,011	€ 10,606	€ 6,119

Segment information - Reconcili

Segment information - Reconciliation of segment Adjusted EBITDA to Group Loss for the Period (Details) - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Segment information
Depreciation and amortization	€ (2,511)	€ (1,612)	€ (6,943)	€ (4,461)
Operating loss	(4,744)	(2,843)	(23,006)	(13,823)
Income taxes expenses	(103)		(232)	(163)
Loss for the period	(5,640)	(4,276)	(24,736)	(15,839)
Operating segment
Segment information
Reportable segment Adjusted EBITDA	9,177	4,157	12,848	10,859
Reportable segment Adjusted EBITDA after corporate expenses	(1,084)	(760)	(13,521)	(4,063)
Operating loss	(4,744)	(2,843)	(23,006)	(13,823)
Financial costs, net	(793)	(1,433)	(1,498)	(1,853)
Income taxes expenses	(103)		(232)	(163)
Loss for the period	(5,640)	(4,276)	(24,736)	(15,839)
Corporate
Segment information
Corporate expenses	(10,261)	(4,917)	(26,369)	(14,922)
Depreciation and amortization	(1,134)	(789)	(3,334)	(2,040)
Sharebased payment expenses
Segment information
Share-based compensation	(1,149)	(471)	(2,542)	(5,299)
Depreciation and amortization
Segment information
Depreciation and amortization	€ (2,511)	€ (1,612)	€ (6,943)	€ (4,461)

Segment information - Additiona

Segment information - Additional information (Details) - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Segment information
Real Estate transfer tax expenses		€ 1,200		€ 1,200
Property, plant and equipment	€ 13,585		€ 13,585		€ 8,376
Right-of-use assets.	23,915		23,915		24,932
-United States
Segment information
Property, plant and equipment	552		552		286
Right-of-use assets.	792		792		€ 1,042
Corporate
Segment information
Real Estate transfer tax expenses			0	€ 1,200
Follow-on public offering | Corporate
Segment information
Share issue related cost	€ 105		€ 278

Other income and expenses - Oth

Other income and expenses - Other operating income (Details) - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Other income and expenses
Government grants	€ 535	€ 363	€ 1,940	€ 1,833
Income from the reversal of provisions				89
Gain on disposal of property, plant and equipment		532		532
Others	144	40	485	169
Total other operating income	€ 679	€ 935	€ 2,425	€ 2,623

Other income and expenses - O_2

Other income and expenses - Other operating expenses (Details) - EUR (€) € in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2019
Other income and expenses
Currency losses	€ 23	€ 60	€ 2
Other	30	131
Total other operating expenses	€ 53	€ 191	€ 2

Other income and expenses - LPC

Other income and expenses - LPC GmbH (Details) - EUR (€) € in Thousands	9 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Other income and expenses
Noncontrolling interests	€ (26)	€ (938)
LPC GmbH
Other income and expenses
Proportion of ownership interest in subsidiary	51.00%
Consideration for disposal of subsidiary	€ 213
Consideration to be paid over time	€ 200
Payment due period (in years)	4 years
Noncontrolling interests	€ (268)
Profit/(loss) allocated to non-controlling interest	€ (101)

Sale and Leaseback transaction

Sale and Leaseback transaction (Details) - EUR (€) € in Thousands	1 Months Ended	3 Months Ended	9 Months Ended
	Jun. 30, 2019	Sep. 30, 2019	Sep. 30, 2019
Sale and Leaseback transaction
Real Estate transfer tax expenses		€ 1,200	€ 1,200
Rostock headquarters building
Sale and Leaseback transaction
Disposal of property	€ 22,778

Trade receivables and other a_3

Trade receivables and other assets (Details) - EUR (€) € in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Non-current
Other assets-Rental deposits	€ 1,853		€ 1,853		€ 1,948
Other assets - Others	100		100
Trade receivables and contract assets and other assets non-current	1,953		1,953		1,948
Current
Trade receivables, net	22,674		22,674		12,709
Contract assets, net	3,113		3,113		3,884
Receivables due from shareholders					2,766
Other assets	4,055		4,055		5,846
Trade receivables and contract assets and other assets current	29,842		29,842		25,205
Total non-current and current trade receivables and contract assets and other assets	31,795		31,795		27,153
Credit loss rates in relation to the outstanding trade receivables and contract assets
Impairment of financial assets	1,147	€ 92	2,821	€ 554
Cash deposits provided as security for bank loans	500		500
Berlin Offices
Credit loss rates in relation to the outstanding trade receivables and contract assets
Bank guarantee	257		257
Trade receivables and contract assets
Credit loss rates in relation to the outstanding trade receivables and contract assets
Financial assets	€ 30,933		€ 30,933		€ 18,928
Expected credit loss rate	16.60%		16.60%		12.30%
Expected credit loss	€ 5,146		€ 5,146		€ 2,335
Trade receivables and contract assets | Not past due
Credit loss rates in relation to the outstanding trade receivables and contract assets
Financial assets	€ 21,273		€ 21,273		€ 11,102
Expected credit loss rate	0.70%		0.70%		0.30%
Trade receivables and contract assets | Past due 1-30 days
Credit loss rates in relation to the outstanding trade receivables and contract assets
Financial assets	€ 1,033		€ 1,033		€ 1,113
Expected credit loss rate	5.90%		5.90%		1.00%
Trade receivables and contract assets | Past due 31-90 days
Credit loss rates in relation to the outstanding trade receivables and contract assets
Financial assets	€ 1,247		€ 1,247		€ 1,708
Expected credit loss rate	10.10%		10.10%		1.20%
Trade receivables and contract assets | Past due more than 90 days
Credit loss rates in relation to the outstanding trade receivables and contract assets
Financial assets	€ 7,380		€ 7,380		€ 5,005
Expected credit loss rate	65.30%		65.30%		45.40%
Minimum
Current
Receivables payment terms			30 days
Maximum
Current
Receivables payment terms			90 days
Other assets
Credit loss rates in relation to the outstanding trade receivables and contract assets
Prepaid expenses	€ 1,483		€ 1,483		€ 3,481
Receivables from grants	1,268		1,268		€ 409
Other assets | Rostock headquarters building
Credit loss rates in relation to the outstanding trade receivables and contract assets
Cash deposits provided as security for bank loans	1,500		1,500
Bank guarantee	3,000		3,000
Other assets | Berlin Offices
Non-current
Other assets-Rental deposits	128		128
Other assets | Certain plant and machineries
Non-current
Other assets-Rental deposits	191		191
Other assets | LPC GmbH
Credit loss rates in relation to the outstanding trade receivables and contract assets
Consideration receivable for the sale of LPC	200		200
Consideration receivable for the sale of LPC due after one year	€ 100		€ 100

Cash and short-term deposits (D

Cash and short-term deposits (Details) - EUR (€) € in Thousands	Sep. 30, 2020	Dec. 31, 2019
Borrowings
Short term deposits pledged as security	€ 500
Secured bank loan
Borrowings
Short term deposits pledged as security	1,500	€ 1,500
Existing Overdraft facility
Borrowings
Short term deposits pledged as security	2,500	2,500
Maximum borrowing capacity	2,500
Second Overdraft facility
Borrowings
Short term deposits pledged as security	1,000	€ 0
Maximum borrowing capacity	€ 500

Equity - Capital Reserves (Deta

Equity - Capital Reserves (Details) € / shares in Units, € in Thousands	1 Months Ended
	Jul. 31, 2020$ / shares	Jul. 31, 2020EUR (€)€ / sharesshares	Sep. 30, 2020EUR (€)
Capital reserve
Share premium included in capital reserve | €			€ 107,499
Follow-on public offering | Common shares | Major purchases of assets
Number of common shares issued (in shares)		3,500,000
Public offering price (in dollars per share) | (per share)	$ 14	€ 12.71
Follow-on public offering | Common shares | Selling shareholders | Major purchases of assets
Number of common shares issued (in shares)		1,500,000
Follow-on public offering | Common shares | The Company | Major purchases of assets
Number of common shares issued (in shares)		2,000,000
Net offering proceeds, after deducting underwriting discounts, commissions and transaction costs | €		€ 22,000

Financial liabilities - Interes

Financial liabilities - Interest-bearing loans (Details) - EUR (€) € in Thousands	Sep. 30, 2020	Dec. 31, 2019
Financial liabilities
Total non-current liabilities	€ 18,553	€ 19,647
Total current liabilities	7,914	7,323
Total non-current and current liabilities	26,467	26,970
Short term deposits pledged as security	500
Total loans
Financial liabilities
Total non-current liabilities	501	1,578
Total current liabilities	4,619	3,688
Secured bank loans
Financial liabilities
Total non-current liabilities	501	968
Total current liabilities	868	802
Short term deposits pledged as security	1,500	1,500
Other bank loans
Financial liabilities
Total current liabilities	406
Total non-current and current liabilities	406
Bank overdrafts
Financial liabilities
Total current liabilities	3,345	2,636
Municipal loans
Financial liabilities
Total non-current liabilities		610
Total current liabilities		250
Lease liabilities
Financial liabilities
Total non-current liabilities	18,052	18,069
Total current liabilities	3,295	3,635
Total non-current and current liabilities	€ 21,347	€ 21,704

Financial liabilities - Conditi

Financial liabilities - Conditions and statement of liabilities (Details) - EUR (€) € in Thousands	Sep. 30, 2020	Dec. 31, 2019
Financial liabilities
Nominal amount	€ 26,467	€ 26,970
Carrying amount	26,467	26,970
Financial assets pledged as collateral for liabilities or contingent liabilities	500
Bank overdrafts	490	476
Secured bank loans
Financial liabilities
Financial assets pledged as collateral for liabilities or contingent liabilities	1,500	1,500
Bank overdrafts	€ 2,405	€ 2,160
Secured bank loans with maturity period 2018 To 25
Financial liabilities
Nominal interest rate (as a percent)	3.95%	3.95%
Nominal amount	€ 1,369	€ 1,770
Carrying amount	€ 1,369	€ 1,770
Other bank loans
Financial liabilities
Nominal interest rate (as a percent)	1.00%	1.00%
Nominal amount	€ 406
Carrying amount	406
Lease liabilities
Financial liabilities
Nominal amount	21,347	€ 21,704
Carrying amount	€ 21,347	€ 21,704
Municipal loan, 2021, one
Financial liabilities
Nominal interest rate (as a percent)	8.00%	8.00%
Nominal interest rate profit (as a percent)	1.50%	1.50%
Nominal interest rate, on losses (as a percent)	0.75%	0.75%
Nominal amount		€ 360
Carrying amount		€ 360
Municipal loan, 2018-2023
Financial liabilities
Nominal interest rate (as a percent)	8.25%	8.25%
Nominal interest rate profit (as a percent)	1.50%	1.50%
Nominal interest rate, on losses (as a percent)	0.75%	0.75%
Nominal amount		€ 500
Carrying amount		500
Repayment of Municipal Loans
Financial liabilities
Nominal amount		€ 860
Bank overdrafts, one
Financial liabilities
Nominal interest rate (as a percent)	4.46%	4.46%
Nominal amount	€ 490	€ 476
Carrying amount	€ 490	€ 476
Bank overdrafts, two
Financial liabilities
Nominal interest rate (as a percent)	3.75%	3.75%
Nominal amount	€ 2,405	€ 2,160
Carrying amount	€ 2,405	€ 2,160
Bank overdrafts, three
Financial liabilities
Nominal interest rate (as a percent)	3.59%	3.59%
Nominal amount	€ 450
Carrying amount	€ 450
Minimum | Lease liabilities
Financial liabilities
Nominal interest rate (as a percent)	5.40%	2.10%
Maximum | Lease liabilities
Financial liabilities
Nominal interest rate (as a percent)	8.90%	3.50%
Existing Overdraft facility
Financial liabilities
Financial assets pledged as collateral for liabilities or contingent liabilities	€ 2,500	€ 2,500
Second Overdraft facility
Financial liabilities
Financial assets pledged as collateral for liabilities or contingent liabilities	€ 1,000	€ 0

Financial liabilities - Trade p

Financial liabilities - Trade payables and other liabilities (Details) - EUR (€) € in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019
Disclosure of reconciliation of liabilities arising from financing activities
Trade payables	€ 12,052		€ 8,554
Government grants (deferred income)	10,646		11,289
Liability for Virtual Stock Option Program			2,769
Contract liabilities	3,134		3,748
Others	9,866		5,258
Trade payables and other liabilities	35,698		31,618
Non-current	9,296		9,941
Current	26,402		21,677
Grants received for investment in property, plant and equipment	390	€ 341
Provision for outstanding invoices	4,675		1,210
Personnel related liabilities for vacation and bonuses	2,662		2,264
VAT payable	963
VAT receivable			1,311
Liabilities for wage and church tax	€ 478		376
IPO
Disclosure of reconciliation of liabilities arising from financing activities
Costs relating to offering			€ 565

Share-based payments - Equity s

Share-based payments - Equity share option 2017 (Equity settled) (Details) - Equity share option 2017 (Equity settled)	9 Months Ended	12 Months Ended
	Sep. 30, 2020Options€ / sharesshares	Dec. 31, 2019
Share-based payments
Number of options granted | Options	805,308
Number of common shares per option granted | shares	1
Exercise price of share options | € / shares	€ 0.12
Lock-up period	180 days
Weighted average remaining contractual life of outstanding share options	9 years 3 months	10 years

Share-based payments - Equity_2

Share-based payments - Equity share option 2019 (Equity settled) (Details) - Equity share option 2019 (Equity settled) - Member of the supervisory board € / shares in Units, € in Thousands	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2020EUR (€)	Sep. 30, 2020EUR (€)	Sep. 30, 2019EUR (€)	Dec. 31, 2019Options€ / sharesshares
Share-based payments
Number of options granted | Options				396,522
Number of common shares per option granted | shares				1
Exercise price of share options				€ 12.58
Vesting period				3 years
Vesting percentage				33.33%
Weighted average remaining contractual life of outstanding share options				10 years
Weighted average fair value of options outstanding				€ 9.08
Share-based payment expense | €	€ 336	€ 1,728	€ 5,299

Share-based payments - Long-Ter

Share-based payments - Long-Term Incentive Plan (Details) € in Thousands	Sep. 11, 2020OptionsUSD ($)$ / shares	Sep. 30, 2020EUR (€)	Sep. 30, 2020EUR (€)	Dec. 31, 2019
Share-based payments
Stock price volatility (as a percent)	75.00%
Risk free interest rate (as a percent)	0.80%
Long-Term Incentive Plan (LTIP)
Share-based payments
Maximum amount of share-based award grants allowed under the plan (as a percent)				13.00%
Additional share-based award grants allowed under the plan (as a percent)				3.00%
Vesting period	10 years
Trading days	20 days
Exercise price | $ / shares	$ 11.60
Share-based payment expense | €		€ 812	€ 812
Long-Term Incentive Plan (LTIP) | Key management personnel
Share-based payments
Number of options granted | Options	87,500
Long-Term Incentive Plan (LTIP) | Chief Executive Officer
Share-based payments
Number of options granted | Options	36,175
Long-Term Incentive Plan (LTIP) | Chief Financial Officer
Share-based payments
Number of options granted | Options	16,250
Long-Term Incentive Plan (LTIP) | Chief Information Officer
Share-based payments
Number of options granted | Options	15,000
Long-Term Incentive Plan (LTIP) | RSUs | Key management personnel
Share-based payments
RSUs granted | $	75,000
Long-Term Incentive Plan (LTIP) | RSUs | Chief Executive Officer
Share-based payments
RSUs granted | $	72,350
Long-Term Incentive Plan (LTIP) | RSUs | Chief Financial Officer
Share-based payments
RSUs granted | $	32,250
Long-Term Incentive Plan (LTIP) | RSUs | Chief Information Officer
Share-based payments
RSUs granted | $	30,000
Long-Term Incentive Plan (LTIP) | Tranche one
Share-based payments
Vesting percentage	0.33%
Long-Term Incentive Plan (LTIP) | Tranche two
Share-based payments
Vesting percentage	0.33%
Long-Term Incentive Plan (LTIP) | Tranche three
Share-based payments
Vesting percentage	0.33%

Commitments (Details)

Commitments (Details) - EUR (€) € in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2020	Dec. 31, 2019
Lease commitments
Total payment obligation	€ 7,131	€ 802
Rostock headquarters building
Lease commitments
Future lease payments to be made		0
Rostock headquarters building | Within one year
Lease commitments
Future lease payments to be made	380
Rostock headquarters building | Within five years
Lease commitments
Future lease payments to be made	1,838
Rostock headquarters building | Later than 5 years
Lease commitments
Future lease payments to be made	5,012
Office equipment and storage spaces | Within one year
Lease commitments
Future lease payments to be made	75	72
Office equipment and storage spaces | Within five years
Lease commitments
Future lease payments to be made	€ 23	€ 36

Contingent Liabilities (Details

Contingent Liabilities (Details) - EUR (€) € in Thousands	9 Months Ended
	Sep. 30, 2020	Nov. 08, 2018
Universitair Medisch Centrum Utrecht
Contingent Liabilities
Disputed amount	€ 1,300	€ 880
State of Mecklenburg-Western Pomerania ("MVP")
Contingent Liabilities
Amounts received on invoices	€ 2,300

Subsequent Event (Details)

Subsequent Event (Details) € in Thousands	Sep. 11, 2020	Oct. 31, 2020USD ($)	Sep. 30, 2020EUR (€)	Sep. 30, 2020EUR (€)
Former Chief Executive Officer | Leadership transition
Subsequent Event
Amount of salary and bonus		$ 565,000
RSUs | Former Chief Executive Officer | Leadership transition
Subsequent Event
Share-based payment expense		$ 620,000
Long-Term Incentive Plan (LTIP)
Subsequent Event
Share-based payment expense | €			€ 812	€ 812
Vesting period	10 years
Long-Term Incentive Plan (LTIP) | RSUs | Grant of RSUs
Subsequent Event
RSUs granted		251,500
Vesting period		3 years
Long-Term Incentive Plan (LTIP) | Options | Former Chief Executive Officer | Leadership transition
Subsequent Event
Share-based payment expense		$ 162,000